Research Article| Volume 7, ISSUE 3, P687-697, September 1987

Download started.


Monitoring of Anti-Inflammatory Drugs

  • Tai C. Kwong
    Corresponding author: Department of Pathology, The University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642
    Associate Professor of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, and Director, Toxicology Laboratory, Strong Memorial Hospital, Rochester, New York
    Search for articles by this author
  • John Baum
    Professor of Medicine and Pediatrics and of Preventive Family and Rehabilitation Medicine, University of Rochester School of Medicine and Dentistry, and Director, Rheumatology and Clinical Immunology Unit, Monroe Community Hospital, Rochester, New York
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      The major problem with establishing drug concentration- effect relationships for the nonsteroidal anti-inflammatory drugs has been the difficulty in quantitating clinical effects of these drugs. Therefore, with the exception of salicylate, therapeutic drug monitoring of the nonsteroidal anti-inflammatory drugs is of limited use at the present time.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aarbaake J.
        Clinical pharmacokinetics of phenylbutazone.
        Clin Pharmacokinet. 1978; 3: 369-380
        • Baber N.
        • Halliday L.D.C.
        • Van Den Heuvel W.J.A.
        • Walker R.W.
        • et al.
        Indomethacin in rheumatoid arthritis: Clinical effects, pharmacokinetics and platelet studies on responders and nonresponders.
        Ann Rheum Dis. 1978; 38: 128-137
        • Baredare M.
        • Cislaghi C.U.
        • Mandilli M.
        • Sereni F.
        Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis.
        Arch Dis Child. 1978; 53: 381
        • Bird H.A.
        • Lowe J.R.
        • Leatham P.A.
        • et al.
        A phenylbutazone dose-finding study.
        Ann Rheum Dis. 1981; 40: 621-622
        • Birkett D.J.
        The importance of unbound drug.
        Agents Actions Suppl. 1985; 17: 79
        • Borga O.
        • Odar-Cederlof I.
        • Rinberger V.
        • Norlin A.
        Protein binding of salicylate in uremic and normal plasma.
        Clin Pharmacol Ther. 1976; 20: 464
        • Brogden R.N.
        • Heel R.C.
        • Pakes G.E.
        • et al.
        Diflunisal: A review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis.
        Drugs. 1980; 19: 84-106
        • Brogden R.N.
        • Heel R.C.
        • Speight T.M.
        • Avery G.S.
        Naproxen up to date: A review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.
        Drugs. 1979; 18: 241-277
        • Brogden R.N.
        • Heel R.C.
        • Speight T.M.
        • Avery G.S.
        Piroxicam: A reappraisal of its pharmacology and therapeutic efficacy.
        Drugs. 1984; 28: 292-323
        • Brooks P.M.
        • Walker J.J.
        • Dick W.C.
        • et al.
        Phenylbutazone: A clinico-pharmacological study in rheumatoid arthritis.
        Br J Clin Pharmacol. 1975; 2: 437-442
        • Brune K.
        Pharmacokinetic factors as causes of variability in response to non-steroidal anti inflammatory drugs.
        Agents Actions Suppl. 1985; 17: 59
        • Cunningham J.L.
        • Leyland M.J.
        • Delamore I.W.
        • Price Evans D.A.
        Acetanilide oxidation in phenylbutazone-associated hypoplastic anaemia.
        Br Med. 1974; 3: 313-317
        • Dalrympla R.W.
        • Stearns F.M.
        Diflunisal interference with determination of salicylate by the Trinder, Abbott TDx, and DuPont aca methods.
        Clin Chem. 1986; 32: 1
        • Day R.O.
        • Furst O.E.
        • Dromgoole S.H.
        • Kaimm B.
        • et al.
        Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis.
        Clin Pharmacol Ther. 1982; 31: 733-740
        • Doughty R.A.
        • Giesecke L.
        • Athreya B.
        Salicylate therapy in juvenile rheumatoid arthritis.
        Am J Dis Child. 1980; 134: 461
        • Ekstrand R.
        • Alvan G.
        • Borga O.
        Concentration dependent plasma protein binding of salicylate in rheumatoid patients.
        Clin Pharmacokinet. 1979; 4: 137
        • Flower R.J.
        • Vane J.R.
        Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetomidol-phenol).
        Nature. 1972; 240: 410
        • Furst D.E.
        Significance of NSAID serum to response relationships.
        Agents Actions Suppl. 1985; 17: 141
        • Greenblatt D.J.
        • Sellers E.M.
        • Koch-Weseer J.
        Importance of protein binding for the interpretation of serum or plasma drug concentrations.
        J Clin Pharmacol. 1982; 22: 259
        • Grennan D.M.
        • Aarons L.
        • Salisbury R.
        Problems with demonstrating NS AID concentration-response relationships.
        Agents Actions Suppl. 1985; 17: 163
        • Grennan D.M.
        • Aarons L.
        • Siddiqui M.
        • et al.
        Dose-reponse study with ibuprofen in rheumatoid arthritis: Clinical and pharmacokinetic findings.
        Br J Clin Pharmacol. 1983; 15: 311-316
        • Hansten P.D.
        • Hayton W.L.
        Effect of antacid and ascorbic acids on serum salicylate concentration.
        J Clin Pharmacol. 1980; 7: 326
        • Helleberg L.
        Clinical pharmacokinetics of indomethacin.
        Clin Pharmacokinet. 1981; 6: 245-258
        • Jacobs C.J.
        • Pesce M.
        Micromeasurement of plasma salicylate in arthritis children.
        Arthritis Rheum. 1978; 21: 129
        • Keegan C.L.
        • Ungemach F.
        • Simpson J.
        • Aden M.
        A fluorescence polarization immunoassay for the quantitation of salicylate.
        Clin Chem. 1985; 6: 942
        • Klinenberg J.R.
        • Miller F.
        Effect of corticosteroids on blood salicylate concentration.
        JAMA. 1965; 194: 601
        • Kwong T.
        • Adams N.
        • Young N.
        Rapid determination of salicylate in serum on a centrifugal analyzer.
        Clin Biochem. 1984; 17: 170
        • Kwong T.C.
        Analysis of acetylsalicylic acid and its metabolites by liquid chromatography.
        J Liquid Chromatogr. 1987; 10: 305
        • Kwong T.C.
        Free drug measurements: Methodology and clinical significance.
        Clin Chim Acta. 1985; 151: 193-216
      1. Kwong TC: Salicylate Measurement: Clinical Usefulness and Methodology. Critical Reviews in Clinical Laboratory Sciences. Boca Raton, CRC Press, in press

        • Lesko L.J.
        • Narang P.K.
        • Yeager L.
        • Cutler N.R.
        Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.
        Eur J Clin Pharmacol. 1985; 28: 339
        • Levy G.
        Pharmacokinetics of salicylate elimination in man.
        J Pharm Sci. 1965; 54: 959
        • Litt I.F.
        • Cuskey W.R.
        Compliance with salicylate therapy in adolescents with juvenile rheumatoid arthritis.
        Am J Dis Child. 1981; 135: 434
        • Lowenthal D.T.
        • Briggs W.A.
        • Levy G.
        Kinetics of salicylate elimination by anephric patients.
        J Clin Invest. 1974; 54: 1221
        • Makela A-L
        • Yrjana T.
        • Mattila M.
        Dosage of salicylates for children with juvenile rheumatoid arthritis.
        Acta Paediatr Scand. 1979; 68: 423
        • Mandeli M.
        • Tognoni G.
        Monitoring plasma concentrations of salicylate.
        Clin Pharmacokinet. 1980; 5: 424
        • Marunaka T.
        • Shibata T.R.
        • Minami Y.
        • Umeno Y.
        Simultaneous determination of phenyl butazone and its metabolites in plasma and urine by high-performance liquid chromatography.
        J Chromatogr. 1980; 183: 331
        • McGill P.E.
        NSAID-plasma concentration monitoring—optimizing treatment of R.A.
        Agents Actions Suppl. 1985; 17: 157
        • Mongan E.
        • Kelly P.
        • Nies K.
        • Porter W.W.
        • et al.
        Tinnitus as an indication of therapeutic serum salicylate levels.
        JAMA. 1973; 226: 142
        • Natelson S.
        Microtechniques of Clinical Chemistry for the Routine Laboratory. Charles C Thomas, Springfield, Illinois1957: 332
        • Olsson B.
        Decreasing serum salicylate concentrations during long term administration of acetylsalicylic acid in healthy volunteers.
        Scand J Rheum. 1983; 12: 81
        • Orme M.L.E.
        Plasma concentrations and therapeutic effect of anti-inflammatory and anti rheumatic drugs.
        Pharmac Ther. 1982; 16: 167
        • Orme M.L.E.
        The relationship between the plasma concentration of non-steroidal anti inflammatory drugs and their therapeutic effects.
        Agents Actions Suppl. 1985; 17: 151
        • Orozco-Alcala J.J.
        • Baum J.
        Regular and enteric coated aspirin: A re-evaluation.
        Arthritis Rheum. 1979; 22: 1034
        • Paalzow L.
        • Edman P.
        • Eekman A.
        • Lindstrom B.
        The activity of diflunisal and dextropro-poxyphene on experiments of pain in man: Relationships between plasma levels and analgesia.
        in: Diflunisal. International Congress and Symposium Series No. 6. Royal Society of Medicine, London1979: 27
        • Paulus H.E.
        • Siegel M.
        • Mongan E.
        • et al.
        Variations of serum concentrations and half-life of salicylate in patients with rheumatoid arthritis.
        Arthritis Rheum. 1971; 14: 527
        • Reynolds R.C.
        • Cuff L.
        Interaction of serum and sodium salicylate: Changes during acute infection and its influence on pharmacological activity.
        lohns Hopkins Hosp Bull. 1960; 107: 278
        • Ritschel W.A.
        • Thompson G.A.
        Monitoring of drug concentration in saliva: A non-invasive pharmacokinetic procedure.
        Methods Find Exp Clin Pharmacol. 1983; 5: 511
        • Rowland M.
        • Riegelman S.
        Determination of acetylsalicylic acid and salicylic acid in plasma.
        J Pharm Sci. 1967; 56: 717
      2. Siegmeth W: Serum concentrations of piroxicam in relation to its clinical effect in patients with chronic polyarthritis. Wiener Med Wochenschr (special issue) 1980, pp 31-35

        • Tainter M.L.
        • Ferris A.V.
        Aspirin in modern therapy. Sterling Drug Company, New York1969: 5
        • Trinder P.
        Rapid determination of salicylate in biological materials.
        Biochem I. 1954; 57: 301
      3. USP DI. Volume 1. Edition 6. Rockville, Maryland, U.S. Pharmacopeial Convention, 1986, p 291

        • Verbeeck R.K.
        • Blackburn I.L.
        • Loewen G.R.
        Clinical pharmacokinetics of non-steroidal anti inflammatory drugs.
        Clin Pharmacokinet. 1983; 8: 297-331
        • Wallis W.J.
        • Simkin P.A.
        Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmocokinetics.
        Clin Pharmacokinet. 1983; 8: 496-522